Aventis
-
Sanofi-aventis and Medicines for Malaria Venture join forces
Sanofi-aventis and Medicines for Malaria Venture (MMV) announced that they have signed an alliance agreement to research malaria treatments as well as the first research project agreement within the framework of the alliance. As part of the agreem…
Aventis | 05 May 2011
-
Sanofi-Aventis acquires Genzyme
Sanofi-aventis announced that it has completed its acquisition of Genzyme Corporation, which is now a wholly-owned subsidiary of Sanofi-aventis. According to the company, Genzyme will become an important new platform in its sustainable growth st…
Aventis | 01 May 2011
-
Sanofi-aventis and Regeneron report positive phase 3 results with zaltrap
Sanofi-aventis and Regeneron Pharmaceuticals Inc announced positive results from the phase 3 velour trial evaluating the investigational agent zaltrap. Zaltrap (aflibercept), also known as VEGF Trap, in combination with the folfiri chemotherapy regim…
Aventis | 27 April 2011
-
Sanofi-Aventis completes acquisition of Genzyme Corporation
Sanofi-aventis announced that it has completed its acquisition of Genzyme Corporation, which is now a wholly-owned subsidiary of Sanofi-aventis. According to the company, Genzyme will become an important new platform in its sustainable growth strateg…
Aventis | 09 April 2011
-
Sanofi-aventis strengthens commitment to ophthalmology
New public private research partnership in the diagnosis, prevention and treatment of ocular diseases
Aventis | 24 March 2011
-
Sanofi-aventis enters into R&D collaboration with UCSF
Sanofi -aventis and the University of California, San Francisco (UCSF) formed two research and development collaborations to more rapidly advance groundbreaking innovation from the lab to the patient. The first collaboration promotes innovative …
Aventis | 18 March 2011
-
Sanofi-aventis, Regeneron report phase 3 lung cancer treatment trial results
Sanofi-aventis and Regeneron Pharmaceuticals Inc announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC). The data showed that …
Aventis | 11 March 2011
-
Sanofi-aventis signs new agreement with WHO to fight neglected tropical diseases
Further $ 25 million donation raises prospects of eliminating sleeping sickness
Aventis | 09 March 2011
-
Sanofi-aventis, Oxford University conduct oncology research in India
Sanofi -aventis US and Oxford University have entered into an agreement to conduct multi-phase oncology clinical and epidemiological research with INDOX, India's leading academic oncology network. Through this partnership, sanofi-aventis US and …
Aventis | 24 February 2011
-
Collaboration on translational biomedical research
Sanofi-aventis is collaborating with Harvard University. The goal is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between Harvard and sanofi-aventis. The focus is translationa…
Aventis | 03 November 2010
